Protocol No. | UW24138 20230005 |
||
---|---|---|---|
Principal Investigator | Serritella, Anthony | ||
Phase | III | ||
Age Group | Adult | ||
ClinicalTrials.Gov | NCT06691984 (Click to jump to clinicaltrials.gov) | ||
Management Group(s) | Genitourinary | ||
Title
Description
Objective
Treatment The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
Key Eligibility
For full study eligibility see this study's ClinicalTrials.gov record.
Applicable Disease Sites
Participating Institutions
|